Trial reportJournal of the American Geriatrics Society2010
Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension.
Trial report in Journal of the American Geriatrics Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Effects of Angiotensin-Converting Enzyme Inhibitors on Arterial Stiffness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Cardiovascular therapeutics · 2020Pooled it
- Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association.Hypertension (Dallas, Tex. : 1979) · 2015Guideline
- Efficacy and Safety of Esaxerenone for Essential Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2025Review
- Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Vascular Aging: Assessment and Intervention.Clinical interventions in aging · 2023Review
- Aortic-to-brachial artery stiffness gradient is not blood pressure independent.Journal of human hypertension · 2019Article
- Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging.Frontiers in endocrinology · 2019Review
- Cellular mechanisms underlying obesity-induced arterial stiffness.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Review
- Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Article
- Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?Current hypertension reports · 2015Review
- Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives.International journal of cardiology. Heart & vessels · 2014Review
- The pathophysiology of hypertension in patients with obesity.Nature reviews. Endocrinology · 2014Review
- The role of tissue Renin-Angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness.Frontiers in endocrinology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo determine the efficacy of spironolactone (SPIRO) and hydrochlorothiazide (HCTZ) as monotherapy in older patients with hypertension in blood pressure (BP) control and measures of vascular stiffness.
designRandomized double-blind trial.
settingUniversity teaching hospital.
participantsForty-five subjects with hypertension (24 men, 21 women, mean age 69).
interventionSix months of HCTZ (n=21) or SPIRO (n=24) therapy titrated to a target systolic BP (SBP) less than 140 mmHg. MEASUREMENTS: Baseline (after 4 weeks of antihypertensive drug washout) and 6-month 24-hour ambulatory BP data were obtained. Pulse pressure (PP) was calculated as the difference between 24-hour average SBP and DBP. Pulse wave velocity (PWV) was determined according to noninvasive recordings of carotid and femoral artery pulse waves.
resultsSix months of HCTZ and SPIRO treatment was associated with significant decreases in 24-hour and nocturnal SBP and diastolic BP (DBP) (analysis of variance (ANOVA) P<.001). At 6 months, average 24-hour and nocturnal SBP were lower in the SPIRO than the HCTZ group (P<.001). PP and PWV also decreased significantly with HCTZ and SPIRO treatments (ANOVA P<.001).
conclusionsSix months of therapy with HCTZ or SPIRO resulted in comparable reductions in 24-hour average and nocturnal SBP and DBP, PP, and PWV in older subjects with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.